Heart failure & cardiomyopathies
A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.72 CI 0.67–0.78Authors' conclusion
Nationwide assessment of therapeutic optimization in heart failure with reduced ejection fraction using the HFC score was feasible and the score was strongly and independently associated with survival.
Study context
- Population
- Danish HFrEF patients alive on July 1, 2018, with ≥365 days for up-titration of medical therapy
- Participants
- 26,779 participants
- Exposure
- Heart Failure Collaboratory (HFC) score ≥median vs <median
- Outcome
- All-cause mortality (risk-adjusted association with HFC composite medical therapy score, range 0-8)
Methodological detailsnationwide
- Nationwide
Main finding
All-cause mortality
Hazard ratio
0.72
CI 0.67–0.78
P < 0.001
≥medianvs <median
HR 0.72 (CI 0.67–0.78); P < 0.001
As reported in the abstract
- Graded inverse association between HFC score and death (restricted cubic spline, fully adjusted Poisson model)
- P < 0.001
Observational data: associations, not effects.
Further findings
Baseline therapy use and HFC score distribution
- ACEi/ARB use
- 77%
- β-blocker use
- 81%
- MRA use
- 30%
- ARNI use
- 2%
- Ivabradine use
- 2%
- Median HFC score
- 4
Original publication
A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study. Circ Heart Fail. Published 25 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →